| Mrs Rohini Grewal, DPT | |
|
1 Wellness Blvd., Suite 204, Irmo, SC 29063 | |
| (803) 749-0808 | |
| (803) 749-0308 |
| Full Name | Mrs Rohini Grewal |
|---|---|
| Gender | Female |
| Speciality | Physical Therapy |
| Experience | 14 Years |
| Location | 1 Wellness Blvd., Irmo, South Carolina |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033424361 | NPI | - | NPPES |
| 426584 | Other | SC | OTHER, MEDICARE PTAN |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Columbia Rehabilitation Clinic, Inc | 2668431644 | 11 |
News Archive
Opexa Therapeutics, Inc., a biotechnology company developing a novel T-cell therapy for multiple sclerosis (MS), announced today that the Company is rebranding its leading MS therapy with the new name Tcelna. The product, previously known as Tovaxin, will now be known as Tcelna as the company positions itself towards the treatment of patients with Secondary Progressive MS (SPMS).
Stromedix, Inc., a biotechnology company focused on innovative therapies for fibrosis and organ failure, announced today that it has exclusively licensed the rights to a monoclonal antibody to integrin αvβ5 from the University of California. This compound is the second Stromedix pipeline asset to be sourced from the laboratory of Dean Sheppard, M.D., at University of California, San Francisco.
Breast cancer is the second most common type of cancer among women in the United States, with approximately 200,000 new diagnoses each year. Early detection is key in the treatment of breast cancer and the biggest advancement for detection in 30 years has arrived at University Hospitals Case Medical Center - tomosynthesis, an innovative technology that provides three-dimensional detailed imaging of the breast.
Positron Corporation a molecular imaging solutions company focused on Nuclear Cardiology, expects the evolution from cardiac SPECT to cardiac PET imaging will be greatly accelerated with the recent changes in reimbursement from the Centers for Medicare & Medicaid Services (CMS) set for 2010.
› Verified 1 days ago
| Provider Name | Columbia Rehabilitation Clinic, Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1598852261 PECOS PAC ID: 2668431644 Enrollment ID: O20041006000102 |
News Archive
Opexa Therapeutics, Inc., a biotechnology company developing a novel T-cell therapy for multiple sclerosis (MS), announced today that the Company is rebranding its leading MS therapy with the new name Tcelna. The product, previously known as Tovaxin, will now be known as Tcelna as the company positions itself towards the treatment of patients with Secondary Progressive MS (SPMS).
Stromedix, Inc., a biotechnology company focused on innovative therapies for fibrosis and organ failure, announced today that it has exclusively licensed the rights to a monoclonal antibody to integrin αvβ5 from the University of California. This compound is the second Stromedix pipeline asset to be sourced from the laboratory of Dean Sheppard, M.D., at University of California, San Francisco.
Breast cancer is the second most common type of cancer among women in the United States, with approximately 200,000 new diagnoses each year. Early detection is key in the treatment of breast cancer and the biggest advancement for detection in 30 years has arrived at University Hospitals Case Medical Center - tomosynthesis, an innovative technology that provides three-dimensional detailed imaging of the breast.
Positron Corporation a molecular imaging solutions company focused on Nuclear Cardiology, expects the evolution from cardiac SPECT to cardiac PET imaging will be greatly accelerated with the recent changes in reimbursement from the Centers for Medicare & Medicaid Services (CMS) set for 2010.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Rohini Grewal, DPT 1 Wellness Blvd, Suite 204, Irmo, SC 29063 Ph: (803) 749-0808 | Mrs Rohini Grewal, DPT 1 Wellness Blvd., Suite 204, Irmo, SC 29063 Ph: (803) 749-0808 |
News Archive
Opexa Therapeutics, Inc., a biotechnology company developing a novel T-cell therapy for multiple sclerosis (MS), announced today that the Company is rebranding its leading MS therapy with the new name Tcelna. The product, previously known as Tovaxin, will now be known as Tcelna as the company positions itself towards the treatment of patients with Secondary Progressive MS (SPMS).
Stromedix, Inc., a biotechnology company focused on innovative therapies for fibrosis and organ failure, announced today that it has exclusively licensed the rights to a monoclonal antibody to integrin αvβ5 from the University of California. This compound is the second Stromedix pipeline asset to be sourced from the laboratory of Dean Sheppard, M.D., at University of California, San Francisco.
Breast cancer is the second most common type of cancer among women in the United States, with approximately 200,000 new diagnoses each year. Early detection is key in the treatment of breast cancer and the biggest advancement for detection in 30 years has arrived at University Hospitals Case Medical Center - tomosynthesis, an innovative technology that provides three-dimensional detailed imaging of the breast.
Positron Corporation a molecular imaging solutions company focused on Nuclear Cardiology, expects the evolution from cardiac SPECT to cardiac PET imaging will be greatly accelerated with the recent changes in reimbursement from the Centers for Medicare & Medicaid Services (CMS) set for 2010.
› Verified 1 days ago